Humira (adalimumab) and AS: clinical trials

In the context of adalimumab's approval for AS in Europe, the results of a one-year study are worth noting: Abbott, adalimumab's manufacturer (as Humira), reports that in a one-year clinical trial, nearly three-quarters of patients with ankylosing spondlyitis responded to treatment with Humira by the end of that year. Press release (Yahoo! News); RTTNews; Associated Press (Houston Chronicle).